Diligent Showcase Launches to Connect Customers with Partners, Integrations and Services to Enhance Their GRC and ESG Programs
Diligent, the global leader in modern governance providing SaaS solutions across governance, risk, compliance, audit and ESG, today announces the launch of Diligent Showcase, a central hub for customers to enhance their GRC and ESG program with more than 50 partners and integrations. The showcase features technology integrations, complementary solutions, and Diligent authorized service providers.
“Diligent Showcase makes it easy for our customers to quickly identify app integrations, solution providers, consultants and independent software vendors that are verified Diligent partners and best positioned to meet their unique business goals,” said Ricardo Moreno, SVP of Worldwide Partnerships at Diligent. “The Showcase underscores our commitment to delivering value to our customers through partnerships and integrations, and also brings visibility to the unique value our partners bring to help our mutual customers better respond to increasing demands for connected GRC solutions.”
Diligent Showcase is an extension of The Diligent Partner Program, the first program to offer partners a single source to meet all their GRC and ESG needs. Using Diligent Showcase, customers can search Diligent’s expansive partner network by region or solution type to find the right partners, integrations, and content to help them tackle the evolving landscape of GRC and ESG. Customers can connect with partners directly or speak with a Diligent expert to find the applications and partners best suited to their needs. Partners in the Diligent Showcase fall into three categories:
- Technology integrations that enable customers to leverage third party solutions within the Diligent platform, such as Clarity AI, Bitsight, S&P Global, Glass Lewis and more.
- Complementary solutions or services that pair with the Diligent platform to enhance an organization’s GRC or ESG program, including Corporation Service Company, Best in Governance (BIG), Board Excellence, Donnelley Financial Solutions (DFIN), Law Debenture and more.
- Solution providers that are trained and authorized to provide Diligent solutions as part of their offerings, including Vertosoft, Turnkey and more.
“Diligent shares our passion for helping organizations stay ahead of global regulatory and compliance requirements, and other business risks, through innovative software,” said Craig Clay, President, Global Capital Markets at Donnelley Financial Solutions (DFIN). “Diligent Showcase allows us to highlight our unique value offerings and reach new customers, furthering our GRC practice.”
“‘Through Bitsight’s integration with Diligent, public and private companies will be able to access market-leading risk data and insights within their Diligent solution, giving them a more holistic view of their cyber risk profile,” said Steve Harvey, CEO at Bitsight. “As the category creator and global leader in the cybersecurity ratings industry, we’re excited to partner with Diligent to help business leaders, risk leaders and boards more confidently navigate the uncertain cyber landscape.”
Learn more about the Diligent Showcase here or become a Diligent partner here.
About Diligent
Diligent is the global leader in modern governance, providing SaaS solutions across governance, risk, compliance, audit and ESG. Empowering more than 1 million users and 750,000 board members and leaders with a holistic view of their organization’s GRC practices so they can make better decisions, faster. No matter the challenge. Learn more at diligent.com.
Follow Diligent on LinkedIn, Twitter and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005174/en/
Contact information
For More Information:
Julia Hanbury
Senior Communications Manager, Diligent
+1 (604) 669-4225
Jhanbury@diligent.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom